

*Hong Kong Exchanges and Clearing Limited, The Stock Exchange of Hong Kong Limited and Hong Kong Securities Clearing Company Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*

*Unless otherwise defined in this announcement, terms used in this announcement shall have the same meanings as those defined in the prospectus dated 17 December 2015 (the “**Prospectus**”) issued by Genscript Biotech Corporation (the “**Company**”).*

*This announcement is for information purposes only and does not constitute an invitation or offer to sell, acquire, purchase or subscribe for securities. Potential investors should read the Prospectus for detailed information about the Company and the Global Offering before deciding whether or not to invest in the Offer Shares.*

*This announcement is not for release, publication, distribution, directly or indirectly, in or into the United States (including its territories and possessions, any state of the United States and the District of Columbia). This announcement does not constitute or form a part of any offer or solicitation to purchase or subscribe for securities in the United States. The Offer Shares have not been, and will not be, registered under the United States Securities Act of 1933, as amended from time to time (the “**U.S. Securities Act**”). The securities may not be offered or sold in the United States except pursuant to registration or an exemption from the registration requirements of the U.S. Securities Act. There will be no public offer of securities in the United States. Any offering of securities to be made in the United States will be made solely to qualified institutional buyers as defined in Rule 144A under the U.S. Securities Act pursuant to an exemption from the registration requirements under the U.S. Securities Act and by means of an offering memorandum that may be obtained from the issuer and that will contain detailed information about the Company and management, as well as financial statements. The Offer Shares are also being offered and sold outside the United States as offshore transactions in accordance with Regulation S under the U.S. Securities Act.*

*In connection with the Global Offering, Haitong International Securities Company Limited, as stabilising manager (the “**Stabilising Manager**”), or any person acting for it, on behalf of the Underwriters, may over-allocate Shares or effect any other transactions with a view to stabilising or maintaining the market price of the Shares at a level higher than that which might otherwise prevail in the open market for a limited period after the Listing Date. However, there is no obligation on the Stabilising Manager, or any person acting for it to conduct any such stabilising action. Such stabilisation action, if commenced, may be effected in all jurisdictions where it is permissible to do so, in each case in compliance with all applicable laws, rules and regulatory requirements, including the Securities and Futures (Price Stabilising) Rules, as amended, made under the Securities and Futures Ordinance. Such stabilisation action, if commenced, will be conducted at the absolute discretion of the Stabilising Manager, or any person acting for it and may be discontinued at any time, and is required to be brought to an end on the 30th day after the last day for the lodging of applications under the Hong Kong Public Offering. The number of Shares being offered in the Global Offering may be increased by up to an aggregate of 60,000,000 Shares (representing in aggregate 15% of the Shares initially being offered under the Global Offering) through the exercise of the Over-allotment Option granted to the International Underwriters by the Company exercisable by the Joint Global Coordinators on behalf of the International Underwriters to cover over-allotment (if any) in the International Offering, which option is exercisable at any time from the date of the International Underwriting Agreement up to (and including) the date which is the 30th day from the last day for lodging applications under the Hong Kong Public Offering.*

*Potential investors should be aware that stabilising action cannot be taken to support the price of the Offer Shares for longer than the stabilisation period which begins on the Listing Date and is expected to expire on Sunday, 17 January 2016, being the 30th day after the date of closing of the application lists under the Hong Kong Public Offering. After this date, no further stabilising action may be taken, demand for the Shares, and therefore the price of the Shares, could fall.*



**Genscript Biotech Corporation**

**金斯瑞生物科技股份有限公司\***

*(incorporated in the Cayman Islands with limited liability)*

**GLOBAL OFFERING**

|                                                         |                                                                                                                                                                                                             |
|---------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| <b>Number of Offer Shares under the Global Offering</b> | <b>: 400,000,000 Shares (subject to the Over-allotment Option)</b>                                                                                                                                          |
| <b>Number of Hong Kong Public Offer Shares</b>          | <b>: 40,000,000 Shares</b>                                                                                                                                                                                  |
| <b>Number of International Offer Shares</b>             | <b>: 360,000,000 Shares (subject to the Over-allotment Option)</b>                                                                                                                                          |
| <b>Offer Price</b>                                      | <b>: HK\$1.31 per Offer Share (payable in full on application, plus a brokerage of 1.0%, an SFC transaction levy of 0.0027% and a Hong Kong Stock Exchange trading fee of 0.005% and subject to refund)</b> |
| <b>Nominal value</b>                                    | <b>: US\$0.001 per Share</b>                                                                                                                                                                                |
| <b>Stock code</b>                                       | <b>: 1548</b>                                                                                                                                                                                               |

**Sole Sponsor**



**Joint Global Coordinators and Joint Bookrunners**



**J.P.Morgan**

**ANNOUNCEMENT OF OFFER PRICE AND ALLOTMENT RESULTS**

\* For identification purposes only